| Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Kjaer S., Linch M., Purkiss A., Kostelecky B., Knowles P.P., Rosse C., Riou P., Soudy C., Kaye S., Patel B. et al.
Biochem. J. 451:329-342(2013) · Mapped (1) |
| A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse. Carlin L.M., Evans R., Milewicz H., Fernandes L., Matthews D.R., Perani M., Levitt J., Keppler M.D., Monypenny J., Coolen T. et al.
Sci Signal 4:ra81-ra81(2011) · Mapped (6) |
| Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., Collazos A., Parker P.J.
PLoS ONE 6:E21732-E21732(2011) · UniProtKB (2) · Mapped (6) |
| The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A. Verma S.K., Ganesan T.S., Kishore U., Parker P.J.
Protein Cell 2:237-249(2011) · Mapped (3) |
| Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry. Tynan C.J., Roberts S.K., Rolfe D.J., Clarke D.T., Loeffler H.H., Kastner J., Winn M.D., Parker P.J., Martin-Fernandez M.L.
Mol. Cell. Biol. 31:2241-2252(2011) · Mapped (19) |
| PKCalpha and PKCdelta regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways. Kveiborg M., Instrell R., Rowlands C., Howell M., Parker P.J.
PLoS ONE 6:e17168-e17168(2011) · Mapped (18) |
| Regulation of the tumour suppressor Fbw7alpha by PKC-dependent phosphorylation and cancer-associated mutations. Durgan J., Parker P.J.
Biochem. J. 432:77-87(2010) · Mapped (10) |
| The late endosome is essential for mTORC1 signaling. Flinn R.J., Yan Y., Goswami S., Parker P.J., Backer J.M.
Mol. Biol. Cell 21:833-841(2010) · Mapped (11) |
| An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation. Rosse C., Formstecher E., Boeckeler K., Zhao Y., Kremerskothen J., White M.D., Camonis J.H., Parker P.J.
PLoS Biol. 7:e1000235-e1000235(2009) · Mapped (10) |
| Protein phosphatase 2A PR130/B''alpha1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. Zwaenepoel K., Goris J., Erneux C., Parker P.J., Janssens V.
FASEB J. 24:538-547(2010) · Mapped (1) |
| Recognition of an intra-chain tandem 14-3-3 binding site within PKCepsilon. Kostelecky B., Saurin A.T., Purkiss A., Parker P.J., McDonald N.Q.
EMBO Rep. 10:983-989(2009) · UniProtKB (1) · Mapped (7) |
| Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. Kermorgant S., Parker P.J.
J. Cell Biol. 182:855-863(2008) · Mapped (29) |
| The regulated assembly of a PKCepsilon complex controls the completion of cytokinesis. Saurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S., Parker P.J.
Nat. Cell Biol. 10:891-901(2008) · UniProtKB (2) · Mapped (2) |
| The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors. Faisal A., Saurin A., Gregory B., Foxwell B., Parker P.J.
J. Biol. Chem. 283:18591-18600(2008) · Mapped (21) |
| The identification and characterization of novel PKCepsilon phosphorylation sites provide evidence for functional cross-talk within the PKC superfamily. Durgan J., Cameron A.J., Saurin A.T., Hanrahan S., Totty N., Messing R.O., Parker P.J.
Biochem. J. 411:319-331(2008) · UniProtKB (1) · Mapped (5) |
| A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. Jefferies H.B., Cooke F.T., Jat P., Boucheron C., Koizumi T., Hayakawa M., Kaizawa H., Ohishi T., Workman P., Waterfield M.D. et al.
EMBO Rep. 9:164-170(2008) · Mapped (1) |
| PIKfyve negatively regulates exocytosis in neurosecretory cells. Osborne S.L., Wen P.J., Boucheron C., Nguyen H.N., Hayakawa M., Kaizawa H., Parker P.J., Vitale N., Meunier F.A.
J. Biol. Chem. 283:2804-2813(2008) · Mapped (1) |
| Novel phosphorylation site markers of protein kinase C delta activation. Durgan J., Michael N., Totty N., Parker P.J.
FEBS Lett. 581:3377-3381(2007) · UniProtKB (1) |
| Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. Calleja V., Alcor D., Laguerre M., Park J., Vojnovic B., Hemmings B.A., Downward J., Parker P.J., Larijani B.
PLoS Biol. 5:e95-e95(2007) · Mapped (3) |
| PKCzetaII is a target for degradation through the tumour suppressor protein pVHL. Iturrioz X., Parker P.J.
FEBS Lett. 581:1397-1402(2007) · Mapped (3) |
| Fab1p and AP-1 are required for trafficking of endogenously ubiquitylated cargoes to the vacuole lumen in S. cerevisiae. Phelan J.P., Millson S.H., Parker P.J., Piper P.W., Cooke F.T.
J. Cell. Sci. 119:4225-4234(2006) · Mapped (12) |
| Differential activation of the PI 3-kinase effectors AKT/PKB and p70 S6 kinase by compound 48/80 is mediated by PKCalpha. Byrne R.D., Rosivatz E., Parsons M., Larijani B., Parker P.J., Ng T., Woscholski R.
Cell. Signal. 19:321-329(2007) · Mapped (4) |
| FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Pardo O.E., Wellbrock C., Khanzada U.K., Aubert M., Arozarena I., Davidson S., Bowen F., Parker P.J., Filonenko V.V., Gout I.T. et al.
EMBO J. 25:3078-3088(2006) · Mapped (7) |
| The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta. Iturrioz X., Durgan J., Calleja V., Larijani B., Okuda H., Whelan R., Parker P.J.
Biochem. J. 397:109-120(2006) · Mapped (5) |
| PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. Ivaska J., Vuoriluoto K., Huovinen T., Izawa I., Inagaki M., Parker P.J.
EMBO J. 24:3834-3845(2005) · UniProtKB (1) · Mapped (6) |
